Neurodegenerative diseases are associated with heterogeneity in genetics, pathology, and
clinical manifestation. Understanding this heterogeneity is particularly relevant for clinical …

Brain aging is a complex process that includes atrophy, vascular injury, and a variety of age-
associated neurodegenerative pathologies, together determining an individual's course of …

Biological subtypes in Alzheimer's disease, originally identified on neuropathological data,
have been translated to in vivo biomarkers such as structural magnetic resonance imaging …

Molecular subtyping of brain tissue provides insights into the heterogeneity of common
neurodegenerative conditions, such as Alzheimer's disease. However, existing subtyping …

Alzheimer's disease (AD) is a complex form of dementia and due to its high phenotypic
variability, its diagnosis and monitoring can be quite challenging. Biomarkers play a crucial …

Ongoing biomarker development programs have been designed to identify serologic or
imaging signatures of clinico-pathologic entities, assuming distinct biological boundaries …

Background Heterogeneity of neurodegenerative diseases, including Alzheimer's disease
(AD), has hampered precision diagnosis and prognosis. Machine learning methods are able …

Alzheimer's disease (AD) neuropathology is extremely heterogeneous, and the evolution
from preclinical to mild cognitive impairment until dementia is driven by interacting …

The population of adults with Alzheimer's disease (AD) varies in needs and outcomes. The
heterogeneity of current AD diagnostic subgroups impedes the use of data analytics in …

The increasing interest in identifying disease biomarkers to understand psychiatric and
neurological conditions has led to large patient registries and cohorts. Traditionally, clinically …